As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.

On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work

outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.

The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.

Xiamen Kingdomway Group Company

Company Overview

COMPANY DESCRIPTION

Xiamen Kingdomway principally manufactures and sells nutritional supplements, but also produces the raw materials for its nutritional products. The company currently has four production bases across China and exports to markets including Singapore and the United States. In 2016, more than 70% of its revenue came from exports.

In 2015, the company took a 51% stake in Doctor’s Best Holdings, Inc. for $35 million. The target company is a California-based nutritional supplements firm. In 2017, the company invested $8.1 million for a 30% stake in Labrada Bodybuilding Nutrition Inc., a Texas-based health supplements company.

GLOBAL FDI EXPERIENCE

As of 2017, the company had invested S$3.8 million (~$2.74 million) to acquire a 95% stake in Pink of Health Pte. Ltd. and Vita Kids Pte. Ltd., both nutrition supplements retailers.